Could Umbilical Cord Tissue Stem Cells Help Treat Parkinson’s Disease in the Future?

While current treatments can help manage these symptoms, they cannot stop or reverse the progression of the disease. This is why researchers around the world are investigating new approaches that could help protect the brain and slow the condition.

One exciting area of research involves mesenchymal stem cells (MSCs) found in umbilical cord tissue.

Key Points

• Researchers are investigating whether umbilical cord tissue stem cells could help protect the brain in Parkinson’s disease.
• These specialised cells may help reduce inflammation, protect nerve cells and support the brain’s natural repair processes.
• Studies have shown encouraging improvements in movement, dopamine levels and nerve cell survival.
• Early clinical trials suggest MSC therapies are generally well tolerated and may offer potential benefits.
• More large-scale clinical trials are now underway to confirm how effective these treatments are and determine the best way to use them safely.

Why Are Cord Tissue Stem Cells So Promising?

Unlike treatments that aim to replace damaged brain cells, researchers believe cord tissue stem cells may work by supporting the brain’s own repair mechanisms.

Mesenchymal stem cells naturally release a wide range of beneficial proteins and signalling molecules that may:

• Reduce harmful inflammation within the brain
• Help protect healthy nerve cells from further damage
• Support the survival of dopamine-producing neurons
• Reduce oxidative stress (damage caused by unstable molecules)
• Improve how brain cells produce and use energy
• Encourage tissue repair

Rather than becoming new brain cells themselves, these stem cells may create a healthier environment that allows existing cells to survive and function more effectively.

What Has Research Found?

A recent 2026 scientific review examined the growing body of research into umbilical cord-derived mesenchymal stem cells (UCMSCs) for Parkinson’s disease.

The researchers found that in laboratory and animal studies, treatment with UCMSCs was associated with:

• Improved movement and motor function
• Higher dopamine levels
• Better survival of dopamine-producing nerve cells
• Reduced inflammation within the brain
• Improved activity of enzymes involved in dopamine production

These findings suggest that cord tissue stem cells could one day play an important role in helping protect the brain from ongoing damage.

What About Clinical Trials?

Research is in its early stages, but progress is encouraging.

Clinical trials are currently investigating stem cell therapies for Parkinson’s disease in several countries, including China, Jordan, Indonesia, and Antigua and Barbuda. Some of these studies are specifically evaluating umbilical cord-derived mesenchymal stem cells.

Earlier clinical trials using mesenchymal stem cells from other sources have generally shown good safety profiles. Some participants also experienced improvements in movement and reductions in markers of inflammation, suggesting these therapies may have beneficial effects beyond symptom management.

While further research is needed, these early results provide optimism for the future.

Looking Ahead

Although cord tissue stem cell therapy for Parkinson’s disease is not yet an established treatment, the research continues to advance at an encouraging pace.

As our understanding grows, umbilical cord tissue stem cells may one day become an important part of regenerative medicine for neurological conditions such as Parkinson’s disease.

For families choosing to preserve their baby’s cord tissue today, ongoing research like this highlights the remarkable therapeutic potential these unique stem cells may hold for the future.

If you’d like to learn more, download our free guide to cord blood and cord tissue banking or speak to one of our specialists.

Reference: Mante N, Undale V, Sanap A, Bhonde R, Kheur S, Tambe P, Kharat A. Advances in Parkinson’s disease management using umbilical cord-derived mesenchymal stem cells. Journal of Neuroimmunology. 2026;416:578911. doi:10.1016/j.jneuroim.2026.578911. PMID: 41861502